adverse event

You have access
Risk Benefit of FOLFIRI Plus Ramucirumab as Third-line and Later-line Treatment of Metastatic Colorectal Cancer
MICHIO KIMURA, EISEKI USAMI, HITOMI TERAMACHI and TOMOAKI YOSHIMURA

Anticancer Research March 2020, 40 (3) 1605-1611; DOI: https://doi.org/10.21873/anticanres.14108
You have access
Therapeutic Outcome of >10 Cycles of Cabazitaxel for Castration-resistant Prostate Cancer: A Multi-institutional Study
MASAKI SHIOTA, MOTONOBU NAKAMURA, AKIRA YOKOMIZO, TOSHIHISA TOMODA, NAOTAKA SAKAMOTO, NARIHITO SEKI, SHUJI HASEGAWA, TAKAKAZU YUNOKI, MASAHIKO HARANO, KENTARO KUROIWA and MASATOSHI ETO

Anticancer Research August 2019, 39 (8) 4411-4414; DOI: https://doi.org/10.21873/anticanres.13612
You have access
Symptomatic Radiation Pneumonitis After Accelerated Partial Breast Irradiation Using Three-dimensional Conformal Radiotherapy
NAOTO SHIKAMA, YU KUMAZAKI, KAZUNARI MIYAZAWA, KAZUNORI MIYAURA, SHINGO KATO, NAOKI NAKAMURA, JIRO KAWAMORI, TAKUYA SHIMIZUGUCHI, NAOKO SAITO and TOSHIAKI SAEKI

Anticancer Research May 2016, 36 (5) 2475-2479;
You have access
Efficacy and Safety Profile of Enzalutamide for Japanese Patients with Castration-resistant Prostate Cancer
MUTSUSHI YAMASAKI, TAKESHI YUASA, SHINYA YAMAMOTO, TATSURO HAYASHI, MASAHIRO OGAWA, MIZUAKI SAKURA, HITOSHI MASUDA, IWAO FUKUI and JUNJI YONESE

Anticancer Research January 2016, 36 (1) 361-365;

Main menu